Antibody Discovery and Protein Engineering, MedImmune, Milstein Building, Granta Park, Cambridge CB21 6GH, UK.
Discovery Sciences, Innovative Medicines and Early Development, AstraZeneca, Darwin Building, Cambridge Science Park, Milton Road, Cambridge CB4 0WG, UK.
Nat Commun. 2017 Jul 14;8:16111. doi: 10.1038/ncomms16111.
Ras mutations are the oncogenic drivers of many human cancers and yet there are still no approved Ras-targeted cancer therapies. Inhibition of Ras nucleotide exchange is a promising new approach but better understanding of this mechanism of action is needed. Here we describe an antibody mimetic, DARPin K27, which inhibits nucleotide exchange of Ras. K27 binds preferentially to the inactive Ras GDP form with a K of 4 nM and structural studies support its selectivity for inactive Ras. Intracellular expression of K27 significantly reduces the amount of active Ras, inhibits downstream signalling, in particular the levels of phosphorylated ERK, and slows the growth in soft agar of HCT116 cells. K27 is a potent, non-covalent inhibitor of nucleotide exchange, showing consistent effects across different isoforms of Ras, including wild-type and oncogenic mutant forms.
Ras 突变是许多人类癌症的致癌驱动因素,但目前仍没有批准的 Ras 靶向癌症治疗方法。抑制 Ras 核苷酸交换是一种很有前途的新方法,但需要更好地了解这种作用机制。在这里,我们描述了一种抗体模拟物 DARPin K27,它可以抑制 Ras 的核苷酸交换。K27 优先与 Ras GDP 形式结合,其 Kd 值为 4 nM,结构研究支持其对失活 Ras 的选择性。K27 的细胞内表达显著减少了活性 Ras 的量,抑制了下游信号转导,特别是磷酸化 ERK 的水平,并减缓了 HCT116 细胞在软琼脂中的生长。K27 是一种有效的非共价核苷酸交换抑制剂,对 Ras 的不同同工型(包括野生型和致癌突变型)均显示出一致的效果。